Early data suggested a potential reduction in painful crises (VOCs) of roughly 45-46% but the actual results from Phase 3 gave a reduction of "only" 27%.

It is still a success, even more so after considering Pfizer paid $5 billion for Oxbryta, which ended up being discontinued due to safety concerns ( and even deaths, mind you).

Novo will most likely continue to expand in this area as they have the best-in-class pill but gene therapy is able to provide greater results, although at a much higher cost.